Short answer
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an 8-K current report with the SEC on October 22, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA-recognized seven-year orphan-drug exclusivity for ONAPGO, protecting market position through February 3, 2032.
SUPERNUS PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA-recognized seven-year orphan-drug exclusivity for ONAPGO, protecting market position through February 3, 2032
- ONAPGO approved for motor fluctuations in adults with advanced Parkinson’s disease
- Supplemental application submitted for a second ONAPGO supplier, targeting potential FDA approval by mid-2027
- Additional supplier could reduce manufacturing concentration and support commercial supply resilience
Item EX-99.1 · Exhibit EX-99.1
- ONAPGO receives seven years of U.S. orphan-drug exclusivity, supporting pricing protection through February 3, 2032
- Exclusivity strengthens Supernus’s commercial position for Parkinson’s motor-fluctuation treatment
- sNDA submitted for a second ONAPGO supplier, targeting potential FDA approval by mid-year 2027
- Additional supplier could reduce manufacturing concentration and improve supply reliability after earlier supply issues
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SUPERNUS PHARMACEUTICALS, INC. 8-K filings
Get the next SUPN 8-K as it lands
Follow SUPN for push alerts, or ask the research agent what this filing means.